/ITRM

ITRM Stock - Iterum Therapeutics plc

Q: What is the analyst price target for ITRM?

Analyst price target information is not currently available for ITRM.

Q: What is ITRM's market cap?

Market capitalization information is not currently available for ITRM.

Healthcare|Biotechnology|NASDAQ

$0.37-2.86%

$0.01 (-2.86%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

SELL

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.41

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ITRM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.91

52W High$2.10

52W Low$0.36

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-254,000	$-1,750,000	$-1,800,000	$-2,104,000	$-161,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-18,696,000	$-47,468,000	$-30,383,000	$-24,537,000	$-32,126,000
Net Income	$-24,774,000	$-38,371,000	$-44,434,000	$-91,564,000	$-52,006,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.26	$-2.96	$-3.63	$-8.41	$-32.49

Company Overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Visit Website

Earnings History & Surprises

ITRM

Beat Rate

61%

Last 18 quarters

Avg Surprise

+12.4%

EPS vs Estimate

Beats / Misses

11/6

1 met exactly

Latest EPS

$-0.20

Q4 2025

EPS Surprise History

Q1 24

+7.8%

$-0.94vs$-1.02

Q2 24

+19.3%

$-0.46vs$-0.57

Q3 24

+42.3%

$-0.30vs$-0.52

Q4 24

-30.4%

$-0.30vs$-0.23

Q1 25

+50.0%

$-0.12vs$-0.24

Q2 25

0.0%

$-0.14vs$-0.14

Q3 25

-23.1%

$-0.16vs$-0.13

Q4 25

-53.8%

$-0.20vs$-0.13

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Feb 6, 2026	$-0.20	—	—	—
Q4 2025	Nov 14, 2025	$-0.13	$-0.20	-53.8%	✗ MISS
Q3 2025	Aug 5, 2025	$-0.13	$-0.16	-23.1%	✗ MISS
Q2 2025	May 13, 2025	$-0.14	$-0.14	0.0%	= MET
Q1 2025	Feb 7, 2025	$-0.24	$-0.12	+50.0%	✓ BEAT
Q4 2024	Nov 14, 2024	$-0.23	$-0.30	-30.4%	✗ MISS
Q3 2024	Aug 14, 2024	$-0.52	$-0.30	+42.3%	✓ BEAT
Q2 2024	May 13, 2024	$-0.57	$-0.46	+19.3%	✓ BEAT
Q1 2024	Mar 28, 2024	$-1.02	$-0.94	+7.8%	✓ BEAT
Q4 2023	Nov 14, 2023	$-0.91	$-0.30	+67.0%	✓ BEAT
Q3 2023	Aug 11, 2023	$-0.80	$-0.95	-18.7%	✗ MISS
Q2 2023	May 12, 2023	$-0.80	$-0.78	+2.5%	✓ BEAT
Q1 2023	Mar 16, 2023	$-1.22	$-0.41	+66.4%	✓ BEAT
Q4 2022	Nov 10, 2022	$-1.00	$-2.38	-138.0%	✗ MISS
Q3 2022	Aug 12, 2022	$-1.05	$-0.60	+42.9%	✓ BEAT
Q2 2022	May 13, 2022	$-0.75	$-0.30	+60.0%	✓ BEAT
Q1 2022	Mar 28, 2022	$-0.60	$-0.30	+50.0%	✓ BEAT
Q4 2021	Nov 12, 2021	$1.80	$0.30	-83.3%	✗ MISS
Q3 2021	Aug 13, 2021	$-0.97	$0.60	+161.9%	✓ BEAT

Frequently Asked Questions about ITRM

What is ITRM's current stock price?

Iterum Therapeutics plc (ITRM) is currently trading at $0.37 per share. The stock has moved -2.86% today.

What is the analyst price target for ITRM?

No analyst price targets are currently available for this stock.

What sector is Iterum Therapeutics plc in?

Iterum Therapeutics plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ITRM's market cap?

Iterum Therapeutics plc has a market capitalization of $0.02 billion, making it a small-cap company.

Does ITRM pay dividends?

No, Iterum Therapeutics plc does not currently pay a dividend to shareholders.